Our results define molecular regulators of intracellular ATG9A trafficking and characterize a lead compound for the treatment of AP-4 deficiency, providing important proof-of-concept data for future Investigational New Drug (IND)-enabling studies. Here, ATG9A is linked to hyperinsulinemic hypoglycemia, familial, 4.